Three-Year Durability of Automated Insulin Delivery Therapy in Children and Adolescents with Type 1 Diabetes: A Multicenter Real-World Study
Introduction: Evidence on the long-term durability of glycemic control beyond the first year of automated insulin delivery therapy remains limited, particularly in large multicenter pediatric cohorts. The present study aimed to evaluate long-term effectiveness and identify determinants of sustained optimal outcomes over 3 years of MiniMed™ 780G use in youth with type 1 diabetes (T1D). Materials and Methods: In this longitudinal, multicenter, real-world study, 359 youth with T1D (median age 12.2 years, 50.9% female) from 20 Italian pediatric diabetes centers were followed for 3 years after MiniMed 780G initiation. Glucose metrics, insulin delivery parameters, device settings, and engagement indicators were analyzed at 1, 2, and 3 years. Longitudinal changes were assessed using linear mixed-effects models. Multivariable logistic regression identified predictors of achieving time in tight range target (TITR ≥ 50%) at 3 years. Results: Median time in range (TIR) remained within international targets but declined modestly from 75% at 1 year to 74% at 3 years ( P = 0.002). The percentage of automatic correction boluses increased over time, whereas user-initiated boluses and carbohydrate entries declined ( P < 0.001). Youth with higher TIR at 1 year showed a progressive reduction in TIR and greater increase in automated corrections (time × group interaction P < 0.001). At 3 years, higher SmartGuard use (odds ratio [OR]: 1.13, 95% confidence interval [CI]: 1.03–1.23; P = 0.007), optimal system settings (OR: 3.21, 95% CI: 1.33–7.77; P = 0.010), and lower automatic correction boluses (OR: 0.84, 95% CI: 0.80–0.89; P < 0.001) were independently associated with achieving TITR ≥50%. Conclusions: MiniMed 780G provides sustained glycemic control over 3 years. However, progressive reliance on automated corrections and reduced user engagement may attenuate tight glycemic control, highlighting the need for ongoing education and proactive device optimization.
Authors
- Giulia Pezzino
- Barbara Felappi
- Giuseppina Salzano (ORCID: https://orcid.org/0000-0003-2180-4510)
- Nicola Minuto (ORCID: https://orcid.org/0000-0002-5280-6319)
- Claudia Arnaldi
- Giulio Maltoni (ORCID: https://orcid.org/0000-0002-2526-5588)
- S Passanisi
- Bruno Bombaci (ORCID: https://orcid.org/0000-0001-8664-1025)
- Andrea Rigamonti (ORCID: https://orcid.org/0000-0003-2557-4150)
- Rosalia Roppolo
- Maurizio Delvecchio (ORCID: https://orcid.org/0000-0002-1528-0012)
- Angela Zanfardino (ORCID: https://orcid.org/0000-0003-0641-1321)
- Eulalia Catamo (ORCID: https://orcid.org/0000-0002-4701-9134)
- Petra Reinstadler
- R Bonfanti
- G V Zuccotti
- Donatella Lo Presti
- Fortunato Lombardo (ORCID: https://orcid.org/0000-0002-7081-5884)
- C Maffeis
- Claudia Piona
- Gianluca Tornese
- Enza Mozzillo
- Chiara Mameli
- Marta Bassi
- ISPED Diabetes Group Study Collaborators
- Mila A. Kalapurackal
Institutions
- University of Messina (IT)
- University of Verona (IT)
- University of Trieste (IT)
- Vita-Salute San Raffaele University (IT)
- University of Milan (IT)
- University of L'Aquila (IT)
- IRCCS Materno Infantile Burlo Garofolo (IT)
- Ospedale di Bolzano (IT)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Ospedale Garibaldi (IT)
- Azienda Sanitaria Locale Viterbo (IT)
- Istituto Ortopedico Gaetano Pini (IT)
- Azienda USL di Bologna (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Policlinico Universitario di Catania (IT)
- Ospedale Pediatrico Giovanni XXIII (IT)
- Azienda di Rilievo Nazionale ed Alta Specializzazione (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- ASST Fatebenefratelli Sacco (IT)
- University of Genoa (IT)
Publication Details
- Journal
- Diabetes Technology & Therapeutics
- Published
- 2026-07-17
- DOI
- https://doi.org/10.1177/15209156261469663
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00